Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions

What Made This Study Different from Oncology

In oncology, patients are often making decisions about survival. Trial participation carries urgency, investigators have clear referral pipelines, and the motivation to enroll is built into the disease itself. Rare rheumatology presents a completely different picture.

Patients with this rare rheumatology condition suffer from chronic pain and reduced quality of life, but they are not facing an immediate threat. Many are already managing their symptoms on existing therapies, particularly in Europe and APAC, where multiple approved options are readily available as part of the standard of care. This is a population that does not typically go looking for clinical trials. They take their medications, manage their discomfort, and continue with their routines.

Asking someone to discontinue a treatment that is at least partially working, in favor of an early-phase study with uncertain benefit, requires a level of engagement that standard feasibility models do not always capture. That dynamic shaped the enrollment landscape for this program. It was not an operational problem to solve. It was a market reality that required a fundamentally different approach to site strategy, country selection, and enrollment planning. Recognizing this early allowed the study team to begin framing expectations more realistically and to advocate for country-level strategy adjustments that aligned with where patients were most likely to be open to new options.

When Feasibility Projections Met Real-World Patient Behavior

The initial country strategy was built on strong investigator relationships and genuine enthusiasm from sites during feasibility. Precision also recommended expanding into Eastern Europe, where standard of care was more limited and patients had fewer treatment alternatives. That recommendation was tabled early on as the sponsor focused on their existing site network.

What emerged over time was a pattern common to non-acute indications. The patients that feasibility conversations had identified did not convert to enrollments at the expected rate. This was not a reflection of site quality or investigator commitment. In markets with robust treatment options, patients simply had less reason to change course. Feasibility projections built on investigator enthusiasm, while well-intentioned, did not fully account for the gap between clinical interest and patient willingness.

The team responded by presenting enrollment data alongside country-level analysis, building a case for the markets they had originally recommended. It took time. A discussion with the client concerning the expansion of the study became a turning point. By then, the team had already laid the groundwork: contracts for select sites were signed, SIVs were scheduled, and CRAs were reaching out to confirm patient availability. When the strategy shifted, the operational infrastructure was already in place.

The Holiday Timing Factor

European sites activated in late November and early December, right before the holiday season. For a non-acute patient population, that timing introduced a natural pause.

Patients managing chronic conditions were unlikely to discontinue working treatments heading into the holidays. Starting a new trial during a period when routines are already disrupted was not a realistic ask for most of this population. The first patient 4 months after the planned date creating a gap between site activation and first enrollment that reflected behavioral patterns rather than site readiness.

Sites were engaged throughout. Outreach was active, advertising was running, and referral networks were in place. The gap was a function of patient decision-making in a non-acute setting, and it reinforced the importance of accounting for seasonal behavior when planning activation timelines in autoimmune indications.

The Protocol Amendment Changed the Math

One of the most impactful pivots came through a protocol amendment that relaxed eligibility criteria. The original design required patients to have had only one prior therapy. As the study progressed, it became clear that the patients most likely to consider an early-phase trial were those who had already cycled through more than one therapy and were actively looking for something different.

Relaxing the previous therapies requirement opened the door to a broader patient pool. At least one patient who had previously screened out was rescreened under the updated criteria and enrolled into the first cohort. That kind of practical, evidence-driven adjustment does not show up in a headline metric, but it fundamentally changed the trajectory of the study.

Bringing Solutions Throughout the Study

Beyond the protocol amendment, the team explored additional strategies to support enrollment on an ongoing basis. Precision's patient engagement team reviewed the sponsor's existing patient-facing materials and offered recommendations for how they might be strengthened. The team also proposed a study engagement lead as a dedicated resource focused on enrollment strategy.

The sponsor opted not to move forward with those particular recommendations at the time, and the team adapted accordingly. Sites continued to run their own outreach efforts and connected with referring consultants. In APAC, a recruitment vendor was brought on board to add another layer of support.

Recommendations were offered consistently and grounded in what the enrollment data was showing. Some were adopted, others informed future planning. The important thing was that ideas kept flowing, and the working relationship supported that kind of ongoing dialogue.

Weekly Calls Became a Portfolio Standard

One of the most consistent differentiators in this program was the weekly one-on-one PM call between the Precision project manager and her sponsor counterpart. These were informal, unbudgeted, and initiated by the PM as a way to stay closely aligned on a fast-moving study.

They became the stabilizing mechanism for the entire program. In a study characterized by frequent strategy updates, ongoing budget discussions, and detailed sponsor involvement in site-level communications, these calls provided a space for early issue surfacing, priority alignment, and collegial problem-solving without requiring full team escalation.

The value was confirmed when the sponsor adopted the same cadence on a separate oncology program after a lessons-learned session. Monthly management calls are the industry norm. Weekly informal touchpoints are not commonly budgeted or practiced. But the pattern is consistent across programs where sponsor relationships are strong and timelines hold despite complexity: teams that communicate more often and more honestly absorb variability without breaking.

Absorbing Change Without Missing a Step

This was a program where operational plans evolved frequently. Country strategies shifted, activation timelines were paused and restarted, budget discussions were ongoing, and communications to investigators received detailed sponsor review. The team adapted to each change while maintaining execution quality across every workstream.

Not a single startup timeline was missed. Every submission was completed on schedule. Site activations exceeded initial projections.

Spain is a useful example. Originally planned for activation in Q2 2026, the approach changed to a conditional model: finalize contracts, hold off on activation until September or October, and activate only if sites could demonstrate patient availability through pre-screening. The team adapted cleanly. Contracts were completed, the regulatory groundwork was preserved, and the option to activate quickly remained intact.

The program achieved several notable milestones during its first year. Final protocol was delivered two days ahead of plan. APAC's full study approval came through nine days earlier than projected. The first APAC site activated nine days after that, and the database go-live was ready two days earlier, ensuring data capture was ready before first patient first visit. In Europe, the CTIS submission on was approved thirteen days ahead of the planned date.

The CTIS submission process generated very few RFIs, reflecting the quality of the regulatory preparation. Global programming coordination ensured EDC was live in time for first dosing. Weekly PM one-on-one calls became a practice adopted across the sponsor's portfolio after their value was demonstrated on this study. A protocol amendment broadened the eligible patient pool in a way that directly supported first cohort enrollment.

• EU CTIS approval received 13 days ahead of the planned timeline, with minimal RFIs during submission.
• Eight healthy volunteer cohorts enrolled on time, back-to-back, without disruption.
• Site activations completed faster than initial estimates across Europe and APAC.
• A protocol amendment broadened the eligible patient pool and directly contributed to first cohort enrollment.
• Weekly PM one-on-one calls became an adopted practice across the sponsor's portfolio after demonstrated value on this study.
• Country strategy evolved based on evidence-based recommendations, with on EU country now active and additional Eastern European markets under evaluation.

Lessons Learned Running Early Phase Autoimmune Studies

This program demonstrates what disciplined execution looks like in a therapeutic area where the familiar playbooks do not always apply. Every startup milestone was met or exceeded. Cohorts enrolled on time. Regulatory submissions were efficient and clean. When the enrollment landscape proved more complex than initial projections suggested, the team adapted through evidence-based strategy adjustments, protocol amendments, and a governance model built on trust and frequent communication.

While the study is ongoing, the lessons it has already produced will inform future autoimmune programs. For sponsors considering early-phase development in autoimmune or inflammatory disease, the experience captured here underscores the value of a partner that understands these programs require more than a standard approach.

• The enrollment dynamics in chronic, non-acute indications are structurally different from what teams encounter in oncology. Patients who are managing their symptoms on existing therapy have a high threshold for change, and that threshold varies significantly by geography depending on what treatment options are locally available.

• Feasibility conversations reflect genuine enthusiasm, and that enthusiasm is a valuable starting point. But the distance between early confidence and enrolled patients can be significant when existing treatments are meeting patient needs. The programs that recalibrate their country strategy based on accumulating enrollment data, rather than holding to original assumptions, tend to find their footing faster.

• Communication cadence can be as important as communication structure. Formal governance has its place, but the weekly informal touchpoints between PM counterparts on this study resolved issues and built alignment in ways that monthly management calls alone could not replicate.

• Operational flexibility is most effective when it is designed into the program from the start. When strategy shifts are anticipated as a natural part of early-phase development rather than treated as disruptions, the team can absorb them without compromising delivery quality or timelines.

If your team is planning early-phase development in autoimmune or inflammatory disease and needs a partner who understands that these studies require more than an oncology playbook, we would welcome a conversation about how we can help.